Journal of Antimicrobial Chemotherapy · 2014 · 120 citations · 37 references
Life SciencesInfectious DiseasesMicrobiologyDiagnostic MicrobiologyMedical MicrobiologyMycologyAntifungal AgentsAntifungal ResistanceAntifungal TherapyAntimicrobial Susceptibility TestingFungal IdentificationFungal InfectionsAntifungal AntibioticsAntifungal Susceptibility TestingCandida Albicans InfectionCandidiasis Drug ResistanceFluconazole TherapyFungal Infection SurveillanceMaldi-tof Mass SpectrometryNon-albicans Candida Species
OBJECTIVES: To define the antifungal susceptibility patterns of the most common non-albicans Candida spp. in China. METHODS: We evaluated the susceptibilities to nine antifungal drugs of Candida parapsilosis species complex, Candida tropicalis, Candida glabrata species complex and Candida krusei isolates from patients with invasive candidiasis at 11 hospitals over 3 years. Isolates were identified by MALDI-TOF MS supplemented by DNA sequencing. MICs were determined by Sensititre YeastOne(TM) using current clinical breakpoints/epidemiological cut-off values to assign susceptibility (or WT), and by CLSI M44-A2 disc diffusion for fluconazole and voriconazole. RESULTS: Of 1072 isolates, 392 (36.6%) were C. parapsilosis species complex. C. tropicalis, C. glabrata species complex and C. krusei comprised 35.4%, 24.3% and 3.7% of the isolates, respectively. Over 99.3% of the isolates were of WT phenotype to amphotericin B and 5-flucytosine. Susceptibility/WT rates to azoles among C. parapsilosis species complex were ≥97.5%. However, 11.6% and 9.5% of C. tropicalis isolates were non-susceptible to fluconazole and voriconazole, respectively (7.1% were resistant to both). Approximately 14.3% of C. glabrata sensu stricto isolates (n = 258) were fluconazole resistant, and 11.6% of C. glabrata sensu stricto isolates were cross-resistant to fluconazole and voriconazole. All C. krusei isolates were susceptible/WT to voriconazole, posaconazole and itraconazole. Overall, 97.7%-100% of isolates were susceptible to caspofungin, micafungin and anidulafungin, but 2.3% of C. glabrata were non-susceptible to anidulafungin. There was no azole/echinocandin co-resistance. Disc diffusion and Sensititre YeastOne(TM) methods showed >95% categorical agreement for fluconazole and voriconazole. CONCLUSIONS: In summary, reduced azole susceptibility was seen among C. tropicalis. Resistance to echinocandins was uncommon.
37
Michael A. Pfaller, Daniel J. Diekema, David L. Gibbs et al. · Journal of Clinical Microbiology · 2010 · 706 citations · Full text
Michael A. Pfaller, Mariana Castanheira, Shawn R. Lockhart et al. · Journal of Clinical Microbiology · 2012 · 373 citations · Full text